Wednesday, April 27, 2022

Screening | Testicular Cancer Follow-Up | Cancer Trends, Cancer Information Highlights, 04/27/2022

National Cancer Institute

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

Cancer Information Highlights
From the National Cancer Institute
Updating you about cancer causes, prevention, screening, treatment, coping, and more
 
New from NCI
Screening for Many Cancers with One Test
  Progress has been made on developing tests that may be able to find many cancers early. But, as NCI's Dr. Phil Castle explains, there's still much to learn about these multi-cancer early detection tests before they become widely used.
Finding Safer Ways to Watch for Cancer after Testicular Cancer Surgery
person in a hospital gown lying on a table   A new study suggests that MRI scans or fewer CT scans can be safely used to monitor for recurrence in people who have had surgery for early-stage testicular cancer.
Cancer Trends Progress Report

This regularly updated report reviews our nation's progress against cancer. New this year are data about sleep, melanoma treatment, outdoor tanning, and evidence-based smoking cessation aids.
Obesity and Cancer

This updated page summarizes the research linking overweight and obesity to the risk of some cancers and discusses how obesity affects cancer survivors.

PDQ Updates
Ovarian Tumor Stages

We've updated the stage descriptions for ovarian germ cell tumors and ovarian low malignant potential tumors on our pages about the treatment of these tumors.
FDA Approvals
Bevacizumab

We've updated our page on bevacizumab with a recent Food and Drug Administration approval. The Alymsys brand of bevacizumab was approved to treat certain types of cervical, colorectal, brain, lung, ovarian, and kidney cancer.
 
Also of Interest
Video: Manufacturing CAR T Cells to Expand Cancer Immunotherapy Research

Only a handful of US research labs are able to make CAR T-cell therapies for use in human studies. That has limited CAR T-cell research. To expand and speed up this immunotherapy research, NCI started a program to make CAR T-cell therapies for use in clinical trials.
Contact Us for Help

Information specialists at NCI's Cancer Information Service (CIS), NCI's contact center, are available to help answer your cancer-related questions in English and Spanish. This page explains how to reach us by phone, chat, or email.

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892 GovDelivery logo

No comments:

Post a Comment